The KEYNOTE-119 study failed to show a survival benefit in TNBC patients. The news comes two months after the FDA gave accelerated approval to a rival, Roche's Tecentriq.
The news closely followed that of the FDA approving the first immunotherapy drug for cancer, Roche's Tecentriq, in combination with Abraxane.
Employees who enjoy their benefits are more inclined to stay with their company. A 2025 Marsh McLennan Agency report said 73% of employees would remain if plan options were better.
The drug received accelerated approval for combination with Celgene's Abraxane based on Phase III data. According to a study, PD-L1-positive patients account for 26 percent of TNBC patients overall.
After his recent appointment to a national health IT advisory committee, Soon-Shiong explained how his life's work is now converging towards major advances in cancer and healthcare more broadly.
The mysterious company just allocated $75 million to its NantCell division - putting some serious funding behind its precision medicine and cancer immunotherapy efforts.
Billionaire investor Patrick Soon-Shiong buys the rights to a next-gen Abraxane from Sorrento Therapeutics - building on the drug that launched his own fortune.
Discover what tools are essential for efficient, safe surgical extractions in today’s health care landscape, from elevators to forceps and beyond.